The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Please provide your email address to receive an email when new articles are posted on . A middle-aged man with type 2 diabetes and no ocular history presented urgently to the New England Eye Center ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback